# Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

> **NCT03415867** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Grupo Espanol de trasplantes hematopoyeticos y terapia celular** · enrollment: 21 (actual)

## Conditions studied

- Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)

## Interventions

- **DRUG:** Glasdegib

## Key facts

- **NCT ID:** NCT03415867
- **Lead sponsor:** Grupo Espanol de trasplantes hematopoyeticos y terapia celular
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-09
- **Primary completion:** 2022-01-09
- **Final completion:** 2022-06-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415867, "Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03415867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*